Chemical Management

The path to Net Zero for Eastern Europe

October 25, 2022

The path
ICIS is the global source of Independent Commodity Intelligence Services. For 150 years, we have connected data, markets, and customers to create a comprehensive, 

Spotlight

Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia’s global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia associated with chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing.

OTHER WHITEPAPERS
news image

THE INTELLIGENT ENTERPRISE FOR THE CHEMICAL INDUSTRY

whitePaper | January 14, 2023

As industries reexamine their partners and processes in a critical search for efficiency, chemical businesses are feeling increasing cost and margin pressure. Still, the companies that can adapt new models and automate their processes have an unprecedented opportunity to have an outsized positive impact.

Read More
news image

PROGRESS IN POLYMER SCIENCE

whitePaper | May 28, 2022

Progress in Polymer Science publishes state-of-the-art overview articles by internationally recognized authorities in polymer science and engineering, one of the fastest growing disciplines.

Read More
news image

How to Deliver Value in the Oil & Gas Sector

whitePaper | July 14, 2021

Every year, oil and gas companies are challenged to build investment portfolios that meet their energy transition goals, fund their hydrocarbon strategy, pay off debt, and reward shareholders. Corporate capital planners must strike the right balance between increasing production and reducing greenhouse gas emissions.

Read More
news image

Hydrogen policy gap

whitePaper | August 10, 2022

The early days of the decarbonised hydrogen industry is seeing a gap emerging between Europe and the US for low-carbon (blue) hydrogen.

Read More
news image

Technologies for PFAS Assessment, Detection,and Treatment

whitePaper | July 20, 2022

PFAS are a large group of heat and stain resistant chemicals, first developed in the 1940s. PFAS are used in a wide range of products, including carpet, nonstick cookware, waterproof clothing, and firefighting foam used at airports and military bases.

Read More
news image

Global Minimum Transparency Standard (GMTS)for hazardous chemicals in products

whitePaper | September 20, 2022

This white paper presents the case for a global standard requiring disclosure of hazardous chemicals used in a product in international trade.

Read More

Spotlight

Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia’s global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia associated with chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing.

Events